Wintermute Biomedical is a biotechnology company that focuses on developing next-generation antimicrobial therapies using the natural power of fatty acids. Their flagship product, Solexan™, is a topical treatment currently undergoing clinical trials for shingles. The company leverages its patented fatty acid-amino acid solubilization technology, which enhances the antibacterial, antifungal, and antiviral properties of fatty acids. Beyond shingles, Wintermute is exploring treatments for antibiotic-resistant infections such as MRSA and Buruli ulcers. The company is committed to addressing unmet medical needs in infectious diseases and operates in both the United States and Australia.